Market Overview:
The global Actonel (Risedronic Acid) market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in the market can be attributed to factors such as an increase in the prevalence of osteoporosis and Paget’s disease of bone, and rising awareness about these diseases. Additionally, increasing investments by key players in research and development for new product launches is also contributing to the growth of this market. However, side effects associated with Actonel (such as gastrointestinal problems) may hamper its uptake among patients, which could restrain the growth of this market to some extent during the forecast period.
 ( CAS 105462-24-6) Industry Outlook.svg)
Product Definition:
Actonel (Risedronic Acid) is a drug used to treat and prevent osteoporosis in postmenopausal women.
5 mg:
5 mg is a white to off-white crystalline powder and is very soluble in water (2.0 g/100 mL). It has a slight odor and taste. It's produced naturally by the kidney, but most of it is made synthetically from ethylenediamine through an enzymatic process called transesterification.
35 mg:
35 mg is used in the treatment of osteoarthritis, rheumatoid arthritis and pain caused by degenerative disc disease. It is also used as an anti-epileptic drug. 35 mg twice a day provides relief from chronic back pain for up to 12 weeks.
Rising geriatric population base worldwide coupled with increasing prevalence of target diseases such as osteoporosis, arthritis.
Application Insights:
Osteoporosis was the prominent application segment in terms of revenue share in 2017. Actonel is used for treating osteoporosis as well as other bone related disorders due to low bone mass. It is primarily used for postmenopausal women and men who have had a hip fracture or who are at risk of developing it. The product helps increase bone density by increasing the rate of absorption and retention of calcium in bones, thereby strengthening them against future fractures.
The others segment includes various applications such as renal osteodystrophy, hypercalcemia, primary hyperparathyroidism (PTHr), secondary hyperparathyroidism (HPTr), vitamin D-resistant rickets (VDRR) & vitamin D-dependent rickets (VDDR).
Regional Analysis:
North America dominated the global actonel market in 2017. The presence of key players, favorable reimbursement policies, and high healthcare expenditure are some of the factors responsible for its largest share. In addition, increasing R&D activities to develop novel therapeutics is expected to fuel growth over the forecast period.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to rising geriatric population and prevalence of osteoporosis & Paget's disease coupled with improving economic conditions in emerging countries such as China & India. Moreover, growing medical tourism industry due to low cost treatment options will also boost demand for RA medication in this region eventually driving market expansion over the next eight years (2018 - 2030).
Europe accounted for a significant share owing bothto high incidence rates as well as large patient base affected by bone diseases such as osteoporosis or Paget's disease which require long term therapy with actonel (risenodic acid).
Growth Factors:
- Increasing geriatric population: The global geriatric population is increasing at a rapid pace and this is expected to drive the demand for Actonel (Risedronic Acid) in the coming years.
- Growing awareness about bone health: There is growing awareness among people about the importance of maintaining healthy bones and this is likely to boost the demand for Actonel (Risedronic Acid) in the near future.
- Rising incidence of osteoporosis: Osteoporosis is a major health concern across the globe and it leads to increased susceptibility to fractures. This will create a high demand for Actonel (Risedronic Acid) in order to prevent fractures in elderly people.
- Technological advancements: The pharmaceutical industry is witnessing rapid advancements in technology which are helping manufacturers develop better drugs such as Actonel (Risedronic Acid). This will help fuel growth of the market during forecast period.
- Increased investment by key players: Key players are investing heavily into research and development activities with an aim to introduce new products in order to cater to unmet needs of patients suffering from osteoporosis
Scope Of The Report
Report Attributes
Report Details
Report Title
Actonel (Risedronic Acid) ( CAS 105462-24-6) Market Research Report
By Type
5 mg, 35 mg, 75 mg, 150 mg
By Application
Osteoporosis, Paget's Disease of Bone, Others
By Companies
Allergan plc (AbbVie Inc.), Takeda, Apotex, Warner Chilcott, Teva Pharmaceutical Industries, Mylan, Macleods Pharmaceuticals Ltd, Aurobindo Pharma, Sun Pharmaceutical Industries Ltd.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
162
Number of Tables & Figures
114
Customization Available
Yes, the report can be customized as per your need.
Global Actonel (Risedronic Acid) ( CAS 105462-24-6) Market Report Segments:
The global Actonel (Risedronic Acid) ( CAS 105462-24-6) market is segmented on the basis of:
Types
5 mg, 35 mg, 75 mg, 150 mg
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Osteoporosis, Paget's Disease of Bone, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Allergan plc (AbbVie Inc.)
- Takeda
- Apotex
- Warner Chilcott
- Teva Pharmaceutical Industries
- Mylan
- Macleods Pharmaceuticals Ltd
- Aurobindo Pharma
- Sun Pharmaceutical Industries Ltd.
 ( CAS 105462-24-6) Market Overview.svg)
Highlights of The Actonel (Risedronic Acid) ( CAS 105462-24-6) Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 5 mg
- 35 mg
- 75 mg
- 150 mg
- By Application:
- Osteoporosis
- Paget's Disease of Bone
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Actonel (Risedronic Acid) ( CAS 105462-24-6) Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 ( CAS 105462-24-6) Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Actonel is a medication used to treat osteoporosis. It works by increasing the production of new bone tissue.
Some of the major players in the actonel (risedronic acid) ( cas 105462-24-6) market are Allergan plc (AbbVie Inc.), Takeda, Apotex, Warner Chilcott, Teva Pharmaceutical Industries, Mylan, Macleods Pharmaceuticals Ltd, Aurobindo Pharma, Sun Pharmaceutical Industries Ltd..
The actonel (risedronic acid) ( cas 105462-24-6) market is expected to register a CAGR of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Actonel (Risedronic Acid) ( CAS 105462-24-6) Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Actonel (Risedronic Acid) ( CAS 105462-24-6) Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Actonel (Risedronic Acid) ( CAS 105462-24-6) Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Actonel (Risedronic Acid) ( CAS 105462-24-6) Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Actonel (Risedronic Acid) ( CAS 105462-24-6) Market Size & Forecast, 2020-2028
4.5.1 Actonel (Risedronic Acid) ( CAS 105462-24-6) Market Size and Y-o-Y Growth
4.5.2 Actonel (Risedronic Acid) ( CAS 105462-24-6) Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 5 mg
5.2.2 35 mg
5.2.3 75 mg
5.2.4 150 mg
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Osteoporosis
6.2.2 Paget's Disease of Bone
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Actonel (Risedronic Acid) ( CAS 105462-24-6) Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Actonel (Risedronic Acid) ( CAS 105462-24-6) Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 5 mg
9.6.2 35 mg
9.6.3 75 mg
9.6.4 150 mg
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Osteoporosis
9.10.2 Paget's Disease of Bone
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 5 mg
10.6.2 35 mg
10.6.3 75 mg
10.6.4 150 mg
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Osteoporosis
10.10.2 Paget's Disease of Bone
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 5 mg
11.6.2 35 mg
11.6.3 75 mg
11.6.4 150 mg
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Osteoporosis
11.10.2 Paget's Disease of Bone
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 5 mg
12.6.2 35 mg
12.6.3 75 mg
12.6.4 150 mg
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Osteoporosis
12.10.2 Paget's Disease of Bone
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 5 mg
13.6.2 35 mg
13.6.3 75 mg
13.6.4 150 mg
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Osteoporosis
13.10.2 Paget's Disease of Bone
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Actonel (Risedronic Acid) ( CAS 105462-24-6) Market: Competitive Dashboard
14.2 Global Actonel (Risedronic Acid) ( CAS 105462-24-6) Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Allergan plc (AbbVie Inc.)
14.3.2 Takeda
14.3.3 Apotex
14.3.4 Warner Chilcott
14.3.5 Teva Pharmaceutical Industries
14.3.6 Mylan
14.3.7 Macleods Pharmaceuticals Ltd
14.3.8 Aurobindo Pharma
14.3.9 Sun Pharmaceutical Industries Ltd.
